{"id":666472,"date":"2023-09-06T11:52:02","date_gmt":"2023-09-06T11:52:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=666472"},"modified":"2023-09-06T11:52:02","modified_gmt":"2023-09-06T11:52:02","slug":"severe-asthma-pipeline-drugs-analysis-report-2023-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-glaxosmithkline-astrazeneca","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/severe-asthma-pipeline-drugs-analysis-report-2023-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-glaxosmithkline-astrazeneca_666472.html","title":{"rendered":"Severe Asthma Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | GlaxoSmithKline, AstraZeneca"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1693934352.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Severe Asthma Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | GlaxoSmithKline, AstraZeneca\" src=\"https:\/\/www.abnewswire.com\/uploads\/1693934352.jpeg\" alt=\"Severe Asthma Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | GlaxoSmithKline, AstraZeneca\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">(Las Vegas, Nevada, United States)  As per DelveInsight\u2019s assessment, globally, Severe Asthma pipeline constitutes key companies continuously working towards developing Severe Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.<\/div>\n<p style=\"text-align: justify;\">The Severe Asthma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-asthma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Severe Asthma Pipeline Insight, 2023<\/a>&#8220;<\/strong> report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Severe Asthma Market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the Severe Asthma Pipeline Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Companies across the globe are diligently working toward developing novel Severe Asthma treatment therapies with a considerable amount of success over the years.&nbsp;<\/li>\n<li>Severe Asthma companies working in the treatment market are <strong>Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, AstraZeneca, Avillion, Novartis, 4D pharma, Roche, Pieris Pharma, Biosion, Avalo Therapeutics<\/strong>, and others, are developing therapies for the Severe Asthma treatment&nbsp;<\/li>\n<li>Emerging Severe Asthma therapies in the different phases of clinical trials are- <strong>LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, PRS-060\/AZD1402, BSI-045B, AVTX-002<\/strong>, and others are expected to have a significant impact on the Severe Asthma market in the coming years.&nbsp;&nbsp;&nbsp;<\/li>\n<li><strong>In March 2021, A 52-week<\/strong>, randomised, double-blind, placebo-controlled, parallel-group, multi-center study of the effectiveness and safety of <strong>GSK3511294<\/strong> adjuvant therapy in adult and adolescent participants with severe uncontrolled asthma with an eosinophilic phenotype was started by GlaxoSmithKline.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Severe Asthma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">The chronic lung disease known as asthma causes the airways to become inflamed and hyperactive. Asthma has a wide range of signs and symptoms that can be brought on by breathing in environmental allergens including pollen, dust, animal dander, mould, or other irritants.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free Sample PDF Report to know more about Severe Asthma Pipeline Therapeutic Assessment-<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/severe-asthma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/report-store\/severe-asthma-pipeline-insight<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Emerging Severe Asthma Drugs Under Different Phases of Clinical Development Include:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>LNR 125.38:<\/strong> Lanier Biotherapeutics<\/li>\n<li><strong>BAT2606:<\/strong> Bio-Thera Solutions<\/li>\n<li><strong>KN-002:<\/strong> Kinaset Therapeutics<\/li>\n<li><strong>CM326:<\/strong> CSPC ZhongQi Pharmaceutical Technology<\/li>\n<li><strong>FB 704A:<\/strong> Oneness Biotech Co., Ltd.<\/li>\n<li><strong>TQC2731:<\/strong> Chia Tai Tianqing Pharmaceutical Group<\/li>\n<li><strong>Masitinib:<\/strong> AB Science<\/li>\n<li><strong>GSK3511294:<\/strong> GlaxoSmithKline<\/li>\n<li><strong>PT010:<\/strong> AstraZeneca<\/li>\n<li><strong>PT027:<\/strong> AstraZeneca and Avillion<\/li>\n<li><strong>CSJ117:<\/strong> Novartis<\/li>\n<li><strong>MRx-4DP0004:<\/strong> 4D pharma<\/li>\n<li><strong>RG6173:<\/strong> Roche<\/li>\n<li><strong>PRS-060\/AZD1402:<\/strong> Pieris Pharma and AstraZeneca<\/li>\n<li><strong>BSI-045B:<\/strong> Biosion<\/li>\n<li><strong>AVTX-002:<\/strong> Avalo Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Severe Asthma Pipeline Therapeutics Assessment<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Severe Asthma Assessment by Product Type<\/li>\n<li>Severe Asthma By Stage and Product Type<\/li>\n<li>Severe Asthma Assessment by Route of Administration<\/li>\n<li>Severe Asthma By Stage and Route of Administration<\/li>\n<li>Severe Asthma Assessment by Molecule Type<\/li>\n<li>Severe Asthma by Stage and Molecule Type<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>DelveInsight&#8217;s Severe Asthma Report covers around products under different phases of clinical development like<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Late-stage products (Phase III)<\/li>\n<li>Mid-stage products (Phase II)<\/li>\n<li>Early-stage product (Phase I)<\/li>\n<li>Pre-clinical and Discovery stage candidates<\/li>\n<li>Discontinued &amp; Inactive candidates<\/li>\n<li>Route of Administration<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Further Severe Asthma product details are provided in the report. Download the Severe Asthma pipeline report to learn more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-asthma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">emerging Severe Asthma therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key companies in the Severe Asthma Therapeutics Market include:<\/strong><\/p>\n<p style=\"text-align: justify;\">Key companies developing therapies for Severe Asthma are &#8211; <strong><em>GSK, AstraZeneca, Avillion, 4D Pharma, Avalo Therapeutics, Biosion, Roche, GenenTech, Boehringer Ingelheim Pharmaceuticals, Amgen, Pfizer, AB Science, Teva Pharmaceuticals, Sanofi, Regeneron Pharmaceuticals, Pieris Pharma, Novartis, Theravance Biopharma, and others.<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Severe Asthma Pipeline Analysis:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Severe Asthma pipeline report provides insights into&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The report provides detailed insights about companies that are developing therapies for the treatment of Severe Asthma with aggregate therapies developed by each company for the same.<\/li>\n<li>It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Severe Asthma Treatment.<\/li>\n<li>Severe Asthma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Severe Asthma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Severe Asthma market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&rsquo;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download Sample PDF Report to know more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-asthma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Severe Asthma drugs and therapies<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Severe Asthma Pipeline Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Increase in the prevalence of Severe Asthma, development of new and innovative treatment options for severe asthma are some of the important factors that are fueling the Severe Asthma Market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Severe Asthma Pipeline Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>However, high cost of asthma medications, poor adherence to treatment, limited efficacy of existing treatments and other factors are creating obstacles in the Severe Asthma Market growth.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of Severe Asthma Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Coverage: Global<\/strong><\/li>\n<li><strong>Key Severe Asthma Companies:<\/strong> Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharmaceutical Technology, Oneness Biotech Co., Ltd., Chia Tai Tianqing Pharmaceutical Group, AB Science, GlaxoSmithKline, AstraZeneca, Avillion, Novartis, 4D pharma, Roche, Pieris Pharma, Biosion, Avalo Therapeutics, and others<\/li>\n<li><strong>Key Severe Asthma Therapies:<\/strong> LNR 125.38, BAT2606, KN-002, CM326, FB 704A, TQC2731, Masitinib, GSK3511294, PT010, PT027, CSJ117, MRx-4DP0004, RG6173, PRS-060\/AZD1402, BSI-045B, AVTX-002, and others<\/li>\n<li><strong>Severe Asthma Therapeutic Assessment:<\/strong> Severe Asthma current marketed and Severe Asthma emerging therapies<\/li>\n<li><strong>Severe Asthma Market Dynamics: Severe Asthma market drivers and Severe Asthma market barriers&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Request for Sample PDF Report for <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/severe-asthma-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Severe Asthma Pipeline Assessment and clinical trials<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Severe Asthma Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Severe Asthma Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Severe Asthma Overview<\/p>\n<p style=\"text-align: justify;\">4. Severe Asthma- Analytical Perspective In-depth Commercial Assessment<\/p>\n<p style=\"text-align: justify;\">5. Severe Asthma Pipeline Therapeutics<\/p>\n<p style=\"text-align: justify;\">6. Severe Asthma Late Stage Products (Phase II\/III)<\/p>\n<p style=\"text-align: justify;\">7. Severe Asthma Mid Stage Products (Phase II)<\/p>\n<p style=\"text-align: justify;\">8. Severe Asthma Early Stage Products (Phase I)<\/p>\n<p style=\"text-align: justify;\">9. Severe Asthma Preclinical Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Severe Asthma Therapeutics Assessment<\/p>\n<p style=\"text-align: justify;\">11. Severe Asthma Inactive Products<\/p>\n<p style=\"text-align: justify;\">12. Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<p style=\"text-align: justify;\">13. Severe Asthma Key Companies<\/p>\n<p style=\"text-align: justify;\">14. Severe Asthma Key Products<\/p>\n<p style=\"text-align: justify;\">15. Severe Asthma Unmet Needs<\/p>\n<p style=\"text-align: justify;\">16 . Severe Asthma Market Drivers and Barriers<\/p>\n<p style=\"text-align: justify;\">17. Severe Asthma Future Perspectives and Conclusion<\/p>\n<p style=\"text-align: justify;\">18. Severe Asthma Analyst Views<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=severe-asthma-pipeline-drugs-analysis-report-2023-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-glaxosmithkline-astrazeneca\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 8774225362<br \/><strong>Address:<\/strong>27 Drydock Ave  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Boston<br \/><strong>State:<\/strong> MA<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\/asset-prioritizaton-services\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=severe-asthma-pipeline-drugs-analysis-report-2023-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-glaxosmithkline-astrazeneca\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Las Vegas, Nevada, United States) As per DelveInsight\u2019s assessment, globally, Severe Asthma pipeline constitutes key companies continuously working towards developing Severe Asthma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/severe-asthma-pipeline-drugs-analysis-report-2023-updates-fda-approvals-clinical-trials-therapies-mechanism-of-action-route-of-administration-by-delveinsight-glaxosmithkline-astrazeneca_666472.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-666472","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/666472","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=666472"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/666472\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=666472"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=666472"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=666472"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}